APPROACHES TO THE TREATMENT OF DIABETIC RETINOPATHY
Main Article Content
Abstract
Year by year, the number of people with diabetes mellitus is increasing in the world, and according to WHO estimates, there are at least 130 million diabetics on the planet today. Moreover, according to the forecasts of this organization, by 2025, this figure will increase to 350 million. At least 2.5 million people live with diabetes in Russia alone. And these official statistics are actually 2-3 times lower than the actual picture of what is happening.In ophthalmology, methods of treating diabetic retinopathy (DR) with modern conservative methods are being actively developed and widely implemented, the combination of which with standard therapy improves the long-term prognosis of the disease. Today, drugs that block vascular endothelial growth factor (VEGF), which is considered the main reason for triggering the mechanism of neovascularization, as well as vascular hyperfiltration into the retina, have become available in wide practice. A detailed study of the properties of VEGF provides an answer to the question of the appropriateness of their use in patients with diabetes mellitus, its effectiveness, as well as potential complications that can pose a serious threat to vision and health in general.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Das A. Diabetic Retinopathy: Battling the Global Epidemic. Investig. Ophthalmol. Vis. Sci. 2016;57:6669–6682. doi: 10.1167/iovs.16-21031. 2. Spencer B.G., Estevez J.J., Liu E., Craig J.E., Finnie J.W. Pericytes, inflammation, and diabetic retinopathy. Inflammopharmacology. 2020;28:697–709. doi: 10.1007/s10787-019-00647-9. 3. Romero-Aroca P., Baget-Bernaldiz M., Pareja-Rios A., Lopez-Galvez M., Navarro-Gil R., Verges R. Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory. J. Diabetes Res. 2016;2016:2156273. doi: 10.1155/2016/2156273. 4. Roy S., Kim D. Retinal capillary basement membrane thickening: Role in the pathogenesis of diabetic retinopathy. Prog. Retin. Eye Res. 2020;82:100903. doi: 10.1016/j.preteyeres.2020.100903. 5. Amoaku W.M., Ghanchi F., Bailey C., Banerjee S., Banerjee S., Downey L., Gale R., Hamilton R., Khunti K., Posner E., et al. Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. Eye. 2020;34:1–51. doi: 10.1038/s41433-020-0961-6. 6. Semeraro F., Morescalchi F., Cancarini A., Russo A., Rezzola S., Costagliola C. Diabetic retinopathy, a vascular and inflammatory disease: Therapeutic implications. Diabetes Metab. 2019;45:517–527. doi: 10.1016/j.diabet.2019.04.002. 7. Behl T., Kotwani A. Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy. Pharmacol. Res. 2015;99:137–148. doi: 10.1016/j.phrs.2015.05.013.
Rodrigues E.B., Farah M.E., Maia M., Penha F.M., Regatieri C., Melo G.B., Pinheiro M.M., Zanetti C.R. Therapeutic monoclonal antibodies in ophthalmology. Prog. Retin. Eye Res. 2009;28:117–144. doi: 10.1016/j.preteyeres.2008.11.005. 9. Filho J.A., Messias A., Almeida F.P., Ribeiro J.A., Costa R.A., Scott I.U., Jorge R. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. Acta Ophthalmol. 2011;89:e567–e572. doi: 10.1111/j.1755-3768.2011.02184.x. 10. Figueira J., Fletcher E., Massin P., Silva R., Bandello F., Midena E., Varano M., Sivaprasad S., Eleftheriadis H., Menon G., et al. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study) Ophthalmology. 2018;125:691–700. doi: 10.1016/j.ophtha.2017.12.008. 11. Lang G.E., Stahl A., Voegeler J., Quiering C., Lorenz K., Spital G., Liakopoulos S. Efficacy and safety of ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic retinopathy-the PRIDE study. Acta Ophthalmol. 2019 doi: 10.1111/aos.14312.
Chatziralli I., Dimitriou E., Theodossiadis G., Kazantzis D., Theodossiadis P. Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: Long-term outcomes of a prospective study. Acta Diabetol. 2020;57:1219–1225. doi: 10.1007/s00592-020-01548-y. 13. Ferraz D.A., Vasquez L.M., Preti R.C., Motta A., Sophie R., Bittencourt M.G., Sepah Y.J., Monteiro M.L., Nguyen Q.D., Takahashi W.Y. A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy. Retina. 2015;35:280–287. doi: 10.1097/IAE.0000000000000363. 14. Cao G., Xu X., Wang C., Zhang S. Sequence effect in the treatment of proliferative diabetic retinopathy with intravitreal ranibizumab and panretinal photocoagulation. Eur. J. Ophthalmol. 2020;30:34–39. doi: 10.1177/1120672118812270. 15. . Comyn O., Wickham L., Charteris D.G., Sullivan P.M., Ezra E., Gregor Z., Aylward G.W., da Cruz L., Fabinyi D., Peto T., et al. Ranibizumab pretreatment in diabetic vitrectomy: A pilot randomised controlled trial (the RaDiVit study) Eye. 2017;31:1253–1258. doi: 10.1038/eye.2017.75.